Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210775 · ClinicalTrials.gov registry record · Phase 1
Topical Imiquimod Treatment of Oral Dysplasia
A Phase 1 study of Oral Dysplasia and Leukoplakia, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07210775 is a Phase 1 study of Oral Dysplasia and Leukoplakia that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07210775, a Phase 1 study of Oral Dysplasia and Leukoplakia, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine the effectiveness of imiquimod in treating oral dysplasia in adult patients. Imiquimod 5% cream could be a safe and practical treatment for oral epithelial dysplasia (a precancerous change in the mouth). The main questions it aims to answer are: 1. Does imiquimod help to make the lesions smaller and make the abnormal cell changes less severe? 2. How can we make this treatment safer and more feasible? Participants will apply topical imiquimod cream to treat the oral dysplasia and receive two follow-up biopsies after the treatment.
Conditions Studied
Interventions
- DRUG Imiquimod (topical use)
Study Locations (1)
California
- OralCare PreCancer and Pain Clinic - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210775
The ClinicalTrials.gov registry entry for NCT07210775 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Oral Dysplasia appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod (topical use) is the first listed.
NCT07210775 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07210775 about?
NCT07210775 is a clinical study titled "Topical Imiquimod Treatment of Oral Dysplasia". The goal of this clinical trial is to determine the effectiveness of imiquimod in treating oral dysplasia in adult patients. Imiquimod 5% cream could be a safe and practical treatment for oral epithelial dysplasia (a precancerous change in the mouth). The main questions it aims to answer are: 1. Do...
What is the current status of trial NCT07210775?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-10-01. Estimated completion is 2027-10-01.
What conditions does trial NCT07210775 study?
This clinical trial studies the following conditions: Oral Dysplasia, Leukoplakia, Leukoplakia Oral.
What interventions are being tested in trial NCT07210775?
The interventions under investigation include: Imiquimod (topical use) (DRUG).
Who is sponsoring clinical trial NCT07210775?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210775 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.